Abstract: New anti-VSIG4 (V-set Ig domain-containing 4) antibodies or an antigen-binding fragments are disclosed. Uses of these antibodies, including methods of treatment, are also provided.
Type:
Application
Filed:
March 3, 2022
Publication date:
May 16, 2024
Applicants:
PIERRE FABRE MEDICAMENT, Y-BIOLOGICS INC.
Inventors:
Noureddine LOUKILI, Florence BAYCHELIER-TINE, Pierre FERRE, Bum-Chan PARK, Jae Eun PARK, Hyun Mi LEE, Soo Young KIM, Hyun Ju LEE
Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said anti-body-drug-conjugate for the treatment of cancer.
Type:
Grant
Filed:
November 15, 2021
Date of Patent:
March 5, 2024
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Ian Rilatt, Michel Perez, Marie Lamothe
Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
Type:
Grant
Filed:
June 22, 2020
Date of Patent:
January 16, 2024
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
John Lippincott, Edward Thein Htun Van Der Horst, Sung Young Kim, Leonard G Presta, Jan-Willem Theunissen
Abstract: The present disclosure provides methods for modulating (e.g., preventing, inhibiting, blocking) the interaction of PSGL-1 and VISTA with agents (e.g., antibodies) that bind to PSGL-1 and/or VISTA.
Type:
Application
Filed:
July 22, 2019
Publication date:
August 3, 2023
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Pierre FERRÉ, Francisco CRUZALEGUI, Noureddine LOUKILI, Olivier DELFOUR, Edward Thein Htun VAN DER HORST
Abstract: The present invention relates to new immunocytokines which are useful for the treatment of cancer. These fusion proteins comprise (i) an antibody or antigen-binding fragment thereof fused to (ii) a cleavable peptide linker, and (iii) cytokine, or functional fragments thereof. Methods of treatment using these immunocytokines are also disclosed.
Type:
Grant
Filed:
April 1, 2020
Date of Patent:
June 13, 2023
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Peter Lowe, Jean-François Haeuw, Alicia Contet, Céline Bertaux, Barbara Akla, Marie-Claire Janin-Bussat, Martine Malissard, Juliette Trepreau
Abstract: The present invention relates to new immunocytokines which are useful for the treatment of cancer. These fusion proteins comprise (i) an antibody or antigen-binding fragment thereof fused to (ii) a cleavable peptide linker, and (iii) cytokine, or functional fragments thereof. Methods of treatment using these immunocytokines are also disclosed.
Type:
Application
Filed:
April 1, 2021
Publication date:
June 8, 2023
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Peter LOWE, Martine MALISSARD, Barbara AKLA, Juliette TREPREAU
Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
Type:
Grant
Filed:
February 26, 2020
Date of Patent:
May 30, 2023
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Thierry Champion, Alain Robert, Marie Lamothe
Abstract: The present invention concerns a compound of following formula (I): where: —R1 is H or OH, —R2 is a (C1-C6)alkyl, COOH, COO—((C1-C6)alkyl) or thiazolyl group, —R3 is H or a (C1-C6)alkyl group, and —R4 is: ?a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among OH and NR5R6, ?—(CH2CH2X1)(CH2CH2X2)a2(CH2CH2X3)a3(CH2CH2X4)a4(CH2CH2X5)a5R7, ?an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or ?a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.
Type:
Application
Filed:
August 11, 2022
Publication date:
January 5, 2023
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Michel PEREZ, Ian RILATT, Marie LAMOTHE
Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said anti-body-drug-conjugate for the treatment of cancer.
Type:
Grant
Filed:
October 28, 2020
Date of Patent:
December 6, 2022
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Ian Rilatt, Michel Perez, Marie Lamothe
Abstract: New anti-VSIG4 (V-set Ig domain-containing 4) antibodies or an antigen-binding fragments are disclosed. Uses of these antibodies, including methods of treatment, are also provided.
Type:
Application
Filed:
September 4, 2020
Publication date:
September 29, 2022
Applicants:
Y-BIOLOGICS INC., PIERRE FABRE MEDICAMENT
Inventors:
Noureddine LOUKILI, Florence BAYCHELIER-TINE, Pierre FERRE, Young Woo PARK, Bum-Chan PARK, Jae Eun PARK, Hyun Mi LEE, Soo Young KIM
Abstract: The present invention relates to an ADC having the following formula (I) in which Ab is an anti-IGF1R antibody characterized in that it comprises light chain CDRs of sequences SEQ ID Nos. 9, 5 and 11, respectively, and heavy chain CDRs of sequences SEQ ID Nos. 7, 2 and 3, respectively, and n is between 1 and 12, for use in the treatment of proliferative diseases, such as cancer, characterized in that the ADC is administered concomitantly with or subsequent to docetaxel.
Abstract: The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
Type:
Grant
Filed:
December 18, 2018
Date of Patent:
June 21, 2022
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Thierry Champion, Alain Robert
Abstract: The present invention relates to a new method for capturing and analysing antibody-drug conjugates (ADCs) in biological samples, such as e.g., serum. Methods for analysing the structure of an antibody-drug conjugate (ADC) in a biological sample and methods for assessing the stability of an ADC are also provided.
Abstract: The invention relates to a use of Copaifera oleoresin for producing a medicament for preventing and/or treating pathologies of the prostate, particularly benign prostatic hyperplasia and/or prostate cancer.
Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
Type:
Application
Filed:
November 15, 2021
Publication date:
April 7, 2022
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-François HAEUW, Marie LAMOTHE
Abstract: The subject matter of the present invention is a novel composition in emulsion form comprising glycerol, vaseline, and liquid paraffin as well as a particular system of preservatives and gelling agents, wherein said composition is characterised by the absence of parabens.
Abstract: The present invention relates to new immunocytokines which are useful for the treatment of cancer. These fusion proteins comprise (i) an antibody or antigen-binding fragment thereof fused to (ii) a cleavable peptide linker, and (iii) cytokine, or functional fragments thereof. Methods of treatment using these immunocytokines are also disclosed.
Type:
Application
Filed:
September 30, 2019
Publication date:
February 17, 2022
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Peter LOWE, Jean-François HAEUW, Alicia CONTET, Céline BERTAUX, Barbara AKLA, Marie-Claire JANIN-BUSSAT
Abstract: The present invention relates to a linker of the following formula (I) or a salt thereof: (I). The present invention relates to a linker-drug conjugate of the following formula (II) or a salt thereof: (II). The present invention relates also to a binding unit-drug corrugate, such as an antibody-drug conjugate, of the following formula (III) or (IV) or a salt thereof: (III), (IV), as well as a pharmaceutical composition comprising such a binding unit-drug corrugate and its use in the treatment of cancer.
Type:
Application
Filed:
September 27, 2019
Publication date:
January 27, 2022
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Michel PEREZ, Frédéric MARION, Jean-François HAEUW, Cyrille DREYFUS
Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drag selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said anti-body-drag-conjugate for the treatment of cancer.
Type:
Grant
Filed:
April 16, 2019
Date of Patent:
January 11, 2022
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-François Haeuw, Marie Lamothe
Abstract: The present invention relates to a transdermal device including porous microparticles capable of containing an active principle, in particular nicotine, and to the use thereof as a drug, in particular for tobacco cessation. The present invention further relates to a method for preparing a transdermal device including porous microparticles filled with an active principle.
Type:
Grant
Filed:
November 16, 2018
Date of Patent:
November 16, 2021
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Isabel Ribeiro Dos Santos, Michel Sournac